03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:07 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) In vitro and cell culture studies identified analogs of the HCV NS3/4A protease complex inhibitor grazoprevir that could help treat drug-resistant HCV infections. Chemical synthesis and testing of grazoprevir analogs...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Company News

Gilead, Ionis Pharmaceuticals, Merck infectious news

A jury in the U.S. District Court for the Northern District of California ordered Gilead to pay $200 million in damages as compensation for infringing upon patents owned by Ionis and Merck covering HCV treatments....
07:00 , Sep 7, 2015 |  BioCentury  |  Strategy

Back to School: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Company News

Merck sales and marketing update

FDA said Victrelis boceprevir from Merck for HCV genotype 1 infection will be discontinued. The small molecule HCV NS3/4A protease inhibitor will be available until about December. Merck reported Victrelis sales of $132 million for...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Vertex sales and marketing update

Vertex will discontinue sales of HCV drug Incivek telaprevir in the U.S. by Oct. 16 in light of available alternative treatments and diminishing market demand, according to a letter sent to healthcare providers. Sales of...
00:24 , Aug 13, 2014 |  BC Extra  |  Company News

Vertex discontinuing Incivek

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) will discontinue sales of HCV drug Incivek telaprevir in the U.S. by Oct. 16 in light of available alternative treatments and diminishing market demand, according to a letter sent to healthcare...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Company News

Express Scripts other news

Pharmacy benefit manager Express Scripts released a list of 66 therapies it will not cover starting Jan.1, 2015. The list includes 25 drugs it previously covered, including anemia drug Epogen epoetin alfa from Amgen Inc....
07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...
01:57 , Aug 5, 2014 |  BC Extra  |  Politics & Policy

Express Scripts releases 2015 formulary

Pharmacy benefit manager Express Scripts Holding Co. (NASDAQ:ESRX) released a list of 66 therapies it will not cover starting Jan.1, 2015. The list includes 25 drugs it previously covered, including anemia drug Epogen epoetin alfa...